HER2+ Breast Cancer: Applying Recent Data Updates to Clinical Practice

Experts explore neoadjuvant HER2+ breast cancer care; delve into treatment goals, predictors, and personalized approaches; and uncover insights on chemotherapy, trastuzumab, and postoperative considerations.

Experts discuss evidence-based strategies in neoadjuvant therapy for HER2+ breast cancer and provide insights on surgery-first considerations, disease size impact, and personalized preoperative regimens.

Experts discuss anthracycline use in HER2+ breast cancer and provide insights into how patient scenarios, heterogeneity, and neuropathy concerns shape considerations in diverse clinical situations.

Experts discuss evolving practices in HER2+ breast cancer care, subcutaneous formulations, patient preferences, and resource conservation.

Health care professionals review considerations in transitioning breast cancer patients to the adjuvant setting and discuss response monitoring, treatment tailoring, and the evolving role of imaging.

Experts analyze adjuvant therapy based on preoperative responses. The discussion unveils standard practices, recent KATHERINE trial data, and considerations for residual disease, offering profound insights into tailoring treatment for improved outcomes.

Experts delve into post–KATHERINE trial discussions, examining data and its impact on residual disease. They highlight unmet needs, emphasizing the ongoing CompassHER2 RD trial’s potential to address challenges, especially regarding brain metastases.

Experts discuss the CLEOPATRA trial outcomes, taxane nuances, and evolving strategies in first-line treatment. They review practical considerations and ongoing trials and dive into the dynamic landscape of managing metastatic HER2+ breast cancer, anticipating transformative developments.

Health care professionals delve into the dynamic landscape of second-line treatments with insights from the DESTINY-Breast03 trial.

Experts explore the intricacies of managing brain metastases in HER2+ breast cancer and delve into the latest evidence, patient considerations, and evolving guidelines for this complex scenario.

Experts share insights on cutting-edge data shaping HER2+ breast cancer care, from the paradigm-shifting HER2CLIMB trial to the promising TUXEDO-1 and ROSET-BD studies; they also uncover advancements in treating patients with brain metastases.

Health care professionals discuss the evolving landscape of HER2+ breast cancer treatments, delving into the complexities of the HER2CLIMB trial and strategies for third- and fourth-line interventions.

Experts analyze the complexities of HER2+ breast cancer treatment, exploring options in the third-line setting and the evolving landscape of antibody-drug conjugates.

Experts review groundbreaking advancements in HER2+ breast cancer treatment, covering curative strategies, metastatic challenges, and the need for ongoing innovation to enhance patient outcomes.